Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Value Health. 2015 Sep;18(6):774-82. doi: 10.1016/j.jval.2015.04.008. Epub 2015 Jun 22.
Value Health. 2015.
PMID: 26409604
Free article.